These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 7684452

  • 1. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
    Boden PR, Higginbottom M, Hill DR, Horwell DC, Hughes J, Rees DC, Roberts E, Singh L, Suman-Chauhan N, Woodruff GN.
    J Med Chem; 1993 Mar 05; 36(5):552-65. PubMed ID: 7684452
    [Abstract] [Full Text] [Related]

  • 2. Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists.
    Singh L, Field MJ, Hill DR, Horwell DC, McKnight AT, Roberts E, Tang KW, Woodruff GN.
    Eur J Pharmacol; 1995 Nov 14; 286(2):185-91. PubMed ID: 8605955
    [Abstract] [Full Text] [Related]

  • 3. Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.
    Horwell DC, Hughes J, Hunter JC, Pritchard MC, Richardson RS, Roberts E, Woodruff GN.
    J Med Chem; 1991 Jan 14; 34(1):404-14. PubMed ID: 1671419
    [Abstract] [Full Text] [Related]

  • 4. Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile.
    Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Pritchard MC, Eden JM, Kneen C, Webdale L, Suman-Chauhan N, Boden P, Singh L, Field MJ, Hill D.
    J Med Chem; 1998 Jan 01; 41(1):38-45. PubMed ID: 9438020
    [Abstract] [Full Text] [Related]

  • 5. Amide bond replacements incorporated into CCK-B selective "dipeptoids".
    Fincham CI, Higginbottom M, Hill DR, Horwell DC, O'Toole JC, Ratcliffe GS, Rees DC, Roberts E.
    J Med Chem; 1992 Apr 17; 35(8):1472-84. PubMed ID: 1573640
    [Abstract] [Full Text] [Related]

  • 6. Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.
    Drysdale MJ, Pritchard MC, Horwell DC.
    J Med Chem; 1992 Jul 10; 35(14):2573-81. PubMed ID: 1635058
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
    Ballaz S, Barber A, Fortuño A, Del Río J, Martin-Martínez M, Gómez-Monterrey I, Herranz R, González-Muñiz R, García-López MT.
    Br J Pharmacol; 1997 Jun 10; 121(4):759-67. PubMed ID: 9208145
    [Abstract] [Full Text] [Related]

  • 8. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.
    Makovec F, Revel L, Letari O, Mennuni L, Impicciatore M.
    Eur J Pharmacol; 1999 Mar 12; 369(1):81-90. PubMed ID: 10204685
    [Abstract] [Full Text] [Related]

  • 9. Development of CCK-B antagonists.
    Horwell DC.
    Neuropeptides; 1991 Jul 12; 19 Suppl():57-64. PubMed ID: 1881533
    [Abstract] [Full Text] [Related]

  • 10. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
    Weng JH, Blommaert AG, Moizo L, Bado A, Ducos B, Böhme A, Garbay C, Roques BP.
    Bioorg Med Chem; 1996 Apr 12; 4(4):563-73. PubMed ID: 8735845
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
    Taniguchi H, Yazaki N, Endo T, Nagasaki M.
    Eur J Pharmacol; 1996 May 23; 304(1-3):147-54. PubMed ID: 8813597
    [Abstract] [Full Text] [Related]

  • 12. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
    Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN.
    Proc Natl Acad Sci U S A; 1990 Sep 23; 87(17):6728-32. PubMed ID: 1975695
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
    Amblard M, Rodriguez M, Lignon MF, Galas MC, Bernad N, Artis-Noël AM, Hauad L, Laur J, Califano JC, Aumelas A.
    J Med Chem; 1993 Oct 01; 36(20):3021-8. PubMed ID: 7692048
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
    Martín-Martínez M, Bartolomé-Nebreda JM, Gómez-Monterrey I, González-Muñiz R, García-López MT, Ballaz S, Barber A, Fortuño A, Del Río J, Herranz R.
    J Med Chem; 1997 Oct 10; 40(21):3402-7. PubMed ID: 9341915
    [Abstract] [Full Text] [Related]

  • 15. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S, Smith AJ, Chapman KL, Fletcher AE, Kemp JA, Marshall GR, Hargreaves RJ, Ryecroft W, Iversen LL, Iversen SD.
    Mol Pharmacol; 1994 Nov 10; 46(5):943-8. PubMed ID: 7969084
    [Abstract] [Full Text] [Related]

  • 16. Are C-terminal octapeptide of cholecystokinin and [Leu11]gastrin-(5-17) different in stimulating acid secretion in isolated rabbit gastric glands?
    Oiry C, Galleyrand JC, Lima-Leite AC, Fulcrand P, Martinez J.
    Eur J Pharmacol; 1995 Dec 29; 294(2-3):511-9. PubMed ID: 8750713
    [Abstract] [Full Text] [Related]

  • 17. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.
    Bickerdike MJ, Marsden CA, Dourish CT, Fletcher A.
    Eur J Pharmacol; 1994 Dec 27; 271(2-3):403-11. PubMed ID: 7705440
    [Abstract] [Full Text] [Related]

  • 18. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O, Maldonado R, Fournie-Zaluski MC, Roques BP.
    J Pharmacol Exp Ther; 1994 Jul 27; 270(1):77-88. PubMed ID: 8035345
    [Abstract] [Full Text] [Related]

  • 19. Rationally designed "dipeptoid" analogues of CCK. A Free-Wilson/Fujita-Ban analysis of some alpha-methyltryptophan derivatives as CCK-B antagonists.
    Higginbottom M, Kneen C, Ratcliffe GS.
    J Med Chem; 1992 May 01; 35(9):1572-7. PubMed ID: 1578483
    [Abstract] [Full Text] [Related]

  • 20. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini.
    Talkad VD, Patto RJ, Metz DC, Turner RJ, Fortune KP, Bhat ST, Gardner JD.
    Biochim Biophys Acta; 1994 Oct 20; 1224(1):103-16. PubMed ID: 7524683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.